Lipid signaling: Sleep, synaptic plasticity, and neuroprotection

Clark, 1992, Enhancement of hippocampal excitatory synaptic transmission by platelet-activating factor, Neuron, 9, 1211, 10.1016/0896-6273(92)90078-R

Kato, 1994, Platelet-activating factor as a potential retrograde messenger in CA1 hippocampal long-term potentiation, Nature, 367, 175, 10.1038/367175a0

Chen, 2002, Cyclooxygenase-2 regulates prostaglandin E2 signaling in hippocampal long-term synaptic plasticity, J Neurophysiol, 87, 2851, 10.1152/jn.2002.87.6.2851

McDermott, 2003, Sleep deprivation causes behavioral, synaptic, and membrane excitability alterations in hippocampal neurons, J Neurosci, 23, 9687, 10.1523/JNEUROSCI.23-29-09687.2003

Marcheselli, 2003, Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression, J Biol Chem, 278, 43807, 10.1074/jbc.M305841200

Mukherjee, 2004, Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress, Proc Nat Acad Sci USA, 101, 8491, 10.1073/pnas.0402531101

Reppert, 2002, Coordination of circadian timing in mammals, Nature, 418, 935, 10.1038/nature00965

Sakai, 2003, A neural mechanism of sleep and wakefulness, Sleep Biol Rhythm, 1, 29, 10.1046/j.1446-9235.2003.00004.x

Hayaishi, 2000, Molecular mechanisms of sleep–wake regulation: a role of prostaglandin D2, Philos Trans R Soc Lond B Biol Sci, 355, 275, 10.1098/rstb.2000.0564

Hayaishi, 2002, Functional genomics of sleep and circadian rhythm invited review: molecular genetic studies on sleep–wake regulation, with special emphasis on the prostaglandin D2 system, J Appl Physiol, 92, 863, 10.1152/japplphysiol.00766.2001

Cravatt, 1995, Chemical characterization of a family of brain lipids that induce sleep, Science, 268, 1506, 10.1126/science.7770779

Mechoulam, 1997, Anandamide may mediate sleep induction, Nature, 89, 25, 10.1038/37891

Murillo-Rodŕiguez, 1998, Anandamide modulates sleep and memory in rats., Brain Res, 812, 270, 10.1016/S0006-8993(98)00969-X

Santucci, 1996, Fur. Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SD141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis, Life Sci, 58, 103, 10.1016/0024-3205(95)02319-4

Valenti, 2004, Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain, Cell Mol Life Sci, 61, 945, 10.1007/s00018-003-3453-5

Stella, 1997, A second endogenous cannabinoid that mediates long-term potentiation, Nature, 388, 773, 10.1038/42015

Bazan, 2003, Synaptic lipid signaling: significance of polyunsaturated fatty acids and platelet-activator, J Lipid Res, 44, 2221, 10.1194/jlr.R300013-JLR200

Prescott, 2000, Platelet-activating factor and related lipid mediators, Annu Rev Biochem, 69, 419, 10.1146/annurev.biochem.69.1.419

Wierazko, 1993, Long-term potentiation in the hippocampus induced by platelet-activating factor, Neuron, 10, 553, 10.1016/0896-6273(93)90342-O

Kato, 1996, Platelet-activating factor as a potential retrograde messenger, J Lipid Med Cell Signal, 14, 341, 10.1016/0929-7855(96)00543-3

Bazan, 1995, A signal terminator, Nature, 374, 501, 10.1038/374501a0

Chen, 2001, Attenuated long-term potentiation in hippocampal dentate gyrus neurons of mice deficient in the platelet-activating factor receptor, J Neurophysiol, 85, 384, 10.1152/jn.2001.85.1.384

Izquierdo, 1995, Memory enhancement by intrahippocampal, intraamygdala or intraentorhinal infusion of platelet-activating factor measured in an inhibitory avoidance, Proc Natl Acad Sci USA, 92, 5047, 10.1073/pnas.92.11.5047

Kornecki, 1988, Neuroregulatory and neuropathological actions of the ether-phospholipid platelet-activating factor, Science, 240, 1792, 10.1126/science.3381103

Bito, 1992, Platelet-activating factor (PAF) receptor in rat brain: PAF mobilizes intracellular Ca2+ in hippocampal neurons, Neuron, 9, 285, 10.1016/0896-6273(92)90167-C

Vane, 1998, Botting RM. Cyclooxygenase 1 and 2, Annu Rev Pharmacol Toxicol, 38, 97, 10.1146/annurev.pharmtox.38.1.97

Chandrasekharan, 2002, COX-3, a Cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression, Proc Natl Acad Sci USA, 99, 13926, 10.1073/pnas.162468699

Bazan, 2002, Lipid signals in pain control, Nature, 420, 135, 10.1038/420135a

Smith, 1996, Prostaglandin endoperoxide H synthases (cyclooxygenase)-1 and -2, J Biol Chem, 271, 33157, 10.1074/jbc.271.17.9906

Dubois, 1998, Van de Putte LBA, Lipsky PE. Cyclooxygenase in biology and disease, FASEB J, 12, 1063, 10.1096/fasebj.12.12.1063

Bazan, 2001, COX-2 as a multifunctional neuronal modulator, Nature Medicine, 7, 414, 10.1038/86477

Ho, 1999, Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease, J Neurosci Res, 57, 295, 10.1002/(SICI)1097-4547(19990801)57:3<295::AID-JNR1>3.0.CO;2-0

Yamagata, 1993, Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids, Neuron, 11, 371, 10.1016/0896-6273(93)90192-T

Hewett, 2000, Cyclooxygenase-2 contributes to N-methyl-d-aspartate-mediated neuronal cell death in primary cortical cell culture, J Pharmacol Exp Ther, 293, 417

Iadecola, 2001, Reduced susceptibility to ischemic brain injury and N-methyl-d-aspartate-mediated neurotoxicity in cyclooxygenase-2 deficient mice, Proc Natl Acad Sci USA, 98, 1294, 10.1073/pnas.98.3.1294

Miettinen, 1997, Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-d-aspartic acid-receptors and phospholipase A2, Proc Natl Acad Sci USA, 94, 6500, 10.1073/pnas.94.12.6500

Nakayama, 1998, Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia, Proc Natl Acad Sci USA, 95, 10954, 10.1073/pnas.95.18.10954

Kaufmann, 1996, COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex, Proc Natl Acad Sci USA, 93, 2317, 10.1073/pnas.93.6.2317

Bezzi, 1998, Prostaglandins stimulate calcium-dependent glutamate release in astrocytes, Nature, 391, 281, 10.1038/34651

Zonta, 2003, Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation, Nat Neurosci., 6, 43, 10.1038/nn980

Boie, 1997, Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes, Eur J Pharmacol, 340, 227, 10.1016/S0014-2999(97)01383-6

Breyer, 2001, Prostanoid receptors: subtypes and signaling, Annu Rev Pharmacol Toxicol, 41, 661, 10.1146/annurev.pharmtox.41.1.661

Narumiya, 1999, Prostanoid receptors: structure, properties, and functions, Physiol Rev, 79, 1193, 10.1152/physrev.1999.79.4.1193

Ahmadi, 2002, PGE2 selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons, Nat Neurosci, 5, 34, 10.1038/nn778

Baba, 2001, Direct activation of rat spinal dorsal neurons by prostaglandin E2, J Neurosci, 21, 1750, 10.1523/JNEUROSCI.21-05-01750.2001

Kozak, 2004, Oxidative metabolism of endocannabinoids by COX-2, Curr Pharmaceutical Design, 10, 659, 10.2174/1381612043453081

Kim, 2004, Inhibition of cyclooxygenases-2 potentiates retrograde endocannabinoid effects in hippocampus, Nat Neurosci, 7, 697, 10.1038/nn1262

Felder, 1998, Cannabinoid receptors and their endogenous agonists, Annu Rev Pharmacol, 38, 179, 10.1146/annurev.pharmtox.38.1.179

Freund, 2003, Role of endogenous cannabinoids in synaptic signaling, Physiol Rev, 83, 1017, 10.1152/physrev.00004.2003

McAllister, 2002, CB1 and CB2 receptor-mediated signaling: a focus on endocannabinoids, Prostaglandins Leukot Essent Fatty Acid, 66, 161, 10.1054/plef.2001.0344

Piomelli, 2003, The molecular logic of endocannabinoid signaling, Nat Rev Neurosci, 4, 873, 10.1038/nrn1247

Sugiura, 2004, Metabolism and physiological significance of anandamide and 2-arachidonoylglycerol, endogenous cannabinoid receptor ligands, 211

Wilson, 2001, Endogenous cannabinoids mediate retrograde signaling at hippocampal synapses, Nature, 410, 588, 10.1038/35069076

Wilson, 2002, Endocannabinoids signaling in the brain, Science, 296, 678, 10.1126/science.1063545

Deadwyler, 1995, Cannabinoids modulate voltage-sensitive potassium A current in hippocampal neurons via a cMP-dependent process, J Pharmacol Exp Ther, 273, 734

Twitchell, 1997, Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons, J Neurophysiol, 78, 43, 10.1152/jn.1997.78.1.43

Hájos, 2002, Cannabinoids inhibit hippocampal GABAerigc transmission and network oscillations, Eur J Neurosci, 12, 3239, 10.1046/j.1460-9568.2000.00217.x

Hoffman, 2000, Mechanisms of cannabinoid inhibition of GABAA synaptic transmission in the hippocampus, J Neurosci, 20, 2470, 10.1523/JNEUROSCI.20-07-02470.2000

Irving, 2000, Functional expression of cell surface cannabinoid CB1 receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons, Neuroscience, 98, 253, 10.1016/S0306-4522(00)00120-2

Bohme, 2000, Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors, Neuroscience, 95, 5, 10.1016/S0306-4522(99)00483-2

Sullivan, 1999, Mechanisms of cannabinoid-receptor-mediated inhibition of synaptic transmission in cultured hippocampal pyramidal neurons, J Neurophysiol, 82, 1286, 10.1152/jn.1999.82.3.1286

Serhan, 2004, Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles on catabasis, Prostaglandins Other Lipid Mediat, 73, 155, 10.1016/j.prostaglandins.2004.03.005

Serhan, 2002, Resolvins: a family of bioactive products of omega-3-fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation, J Biol Chem, 196, 1025